The NEC baby formula lawsuit landscape shifted dramatically this spring, and it is about to shift again. On April 9, 2026, a Cook County jury handed four families a combined $70 million verdict against Abbott Laboratories — the third major plaintiff victory in state court and the first multi-family Illinois trial in this litigation’s history. Now, just days away, the federal docket faces its own inflection point: Inman v. Mead Johnson, the first Enfamil case to survive federal summary judgment, is scheduled to begin jury selection on July 6, 2026. With a Missouri appellate court upholding a $495 million verdict, the only defense win in the entire litigation erased by a misconduct ruling, and a Bloomberg Intelligence estimate placing total liability at $3 billion, families and legal observers are watching every courtroom closely. Here is everything you need to understand about where this litigation stands — and where it is headed.
The April 9 Cook County Verdict: What the $70M Win Means
The Cook County verdict was a milestone on multiple fronts. Four families whose premature infants developed necrotizing enterocolitis (NEC) — a severe, life-threatening gastrointestinal disease that destroys intestinal tissue primarily in preterm babies — pursued their claims together in the first consolidated multi-family NEC trial in Illinois state court. The jury awarded $53 million in compensatory damages and an additional $17 million in punitive damages, totaling $70 million. All four infants survived, but three required surgery and all suffered severe, lasting complications after being fed Abbott’s Similac Special Care 24 in Chicago-area NICUs.
The punitive damages component is particularly significant. The court permitted punitive damages after finding evidence that Abbott may have concealed the NEC risks associated with Similac Special Care 24 from parents and NICU providers. That finding echoes the core allegation running through every NEC baby formula lawsuit filed across the country: that Abbott and Mead Johnson knew cow’s milk-based premature infant formula significantly elevated NEC risk compared to human breast milk fortifiers, yet failed to provide adequate warnings. If you are assessing the potential value of a defective product injury claim involving a NICU infant, a medical malpractice calculator can help you model the range of compensatory and punitive outcomes based on injury severity and jurisdiction.
Abbott maintains that the FDA has found no conclusive evidence linking its formula to NEC and points to independent research in its defense. The company has signaled it will appeal the Cook County verdict, consistent with its posture following earlier adverse state-court rulings.
The Federal Docket: Three Defense Wins, Then a Turning Point
Understanding why Inman v. Mead Johnson matters requires understanding what came before it. MDL 3026 — formally In re Abbott Laboratories et al., Preterm Infant Nutrition Products Liability Litigation — is consolidated in the Northern District of Illinois before Judge Rebecca Pallmeyer. As of June 2026, the MDL contains 798 active cases. Abbott won the first three federal bellwether trials on summary judgment in 2025, with Judge Pallmeyer excluding plaintiffs’ causation experts under the rigorous Daubert standard in each instance. Those rulings left the federal docket looking precarious for plaintiffs.
Then came the fourth bellwether. Inman v. Mead Johnson (Case No. 1:22-cv-037370) involves Alexis Inman, whose son Daniel died after NICU staff transitioned him from fortified breast milk to exclusive Enfamil Premature feedings. Judge Pallmeyer denied Mead Johnson’s summary judgment motion — making this the first federal Enfamil case to survive the court’s causation gauntlet — and critically preserved the testimony of plaintiffs’ epidemiology expert Dr. Logan Spector. That Daubert ruling protecting Dr. Spector’s opinions is the mechanical key that unlocked the courtroom door. For the 798 families in the MDL, the outcome of the July 6 trial could determine whether the federal docket becomes a viable settlement driver or remains a graveyard for plaintiff claims. Federal MDL procedures allow bellwether verdicts to inform global settlement negotiations precisely because they test the strength of representative claims across the broader docket.
State-Court Scoreboard: $625M+ in Verdicts and a Misconduct Bombshell
The state courts have been far more hospitable to plaintiffs than the federal docket — and the numbers reflect it. The table below summarizes every major verdict in the NEC baby formula lawsuit litigation through June 2026.
| Trial | Defendant | Product | Venue | Verdict Date | Amount |
|---|---|---|---|---|---|
| Illinois Enfamil Trial | Mead Johnson | Enfamil | Illinois State Court | March 2024 | $60 million |
| Gill v. Abbott (Missouri) | Abbott | Similac Special Care 24 | Missouri State Court | July 2024 | $495 million ($95M comp + $400M punitive) |
| Cook County Multi-Family Trial | Abbott | Similac Special Care 24 | Cook County, Illinois | April 9, 2026 | $70 million ($53M comp + $17M punitive) |
| Combined State Verdicts | — | — | — | — | $625 million+ |
Beyond the headline numbers, two additional developments reinforced plaintiff momentum. First, a Missouri appellate court upheld the $495 million Gill verdict in full — affirming both the $95 million compensatory award and the $400 million punitive damages finding. The appellate ruling signals that Missouri courts view the punitive damages amount as legally defensible, which matters enormously as defendants consider global settlement math. Second, what had been defendants’ only courtroom victory — a St. Louis defense verdict in October 2024 — was subsequently overturned by a Missouri judge who found that the defense had engaged in misconduct and misled the jury. Abbott and Mead Johnson are appealing that reversal, but for now, there is not a single clean defense win anywhere in the NEC baby formula lawsuit litigation. According to Cornell Law School’s Legal Information Institute, punitive damages are awarded specifically to punish defendants for particularly egregious conduct — findings that, when upheld on appeal, carry significant weight in mass tort settlement negotiations.
In fatal NEC cases where an infant did not survive, families navigating the financial dimensions of a wrongful death claim may benefit from using a wrongful death calculator to understand how courts have historically valued similar losses, including loss of future companionship and parental grief damages.
What Comes Next: The July 6 and August 10 Federal Trials
The immediate focus is Inman v. Mead Johnson, beginning July 6, 2026. The case is widely regarded as the most consequential pending federal event in this litigation’s history for a straightforward reason: it is the first federal trial where plaintiff causation experts have survived Daubert scrutiny and will actually testify before a jury. The stakes are asymmetric. A plaintiff verdict in Inman would validate Dr. Spector’s epidemiological methodology, create immediate pressure on Mead Johnson and Abbott to open global settlement discussions, and likely accelerate resolution of the 798 MDL cases. A defense verdict, by contrast, would suggest that even a surviving bellwether cannot convert causation evidence into jury persuasion — substantially weakening settlement leverage for federal plaintiffs.
Assuming Inman proceeds to verdict, the second federal bellwether — Kelton v. Abbott — is scheduled to begin August 10, 2026. Kelton involves a California family whose premature daughter suffered permanent injuries after being fed Similac in the NICU, making it a Similac-specific test in the federal system. The sequencing matters: two federal trials within six weeks of each other, with state-court verdicts already totaling more than $625 million, creates a compounding pressure dynamic that mass tort defendants typically find unsustainable without structured settlement talks. CDC data on premature birth illustrates the scale of the at-risk population — roughly one in ten U.S. births is preterm, the demographic most affected by NEC — underscoring why the liability pool in this litigation is so large.
Bloomberg Intelligence has estimated that Abbott and Mead Johnson may ultimately face a combined $3 billion in total NEC liability to resolve all claims. No global federal settlement has been announced as of June 2026. With the MDL’s bellwether process now producing its first trial-ready federal case, the gap between that $3 billion estimate and zero settlement discussions is the defining tension of this litigation heading into the second half of 2026.
Frequently Asked Questions About the NEC Baby Formula Lawsuit
What is the NEC baby formula lawsuit, and who can file one?
The NEC baby formula lawsuit is a mass tort action filed by families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow’s milk-based premature infant formulas — primarily Abbott’s Similac Special Care and Mead Johnson’s Enfamil Premature — in hospital NICUs. Claims allege that both manufacturers failed to adequately warn parents and NICU medical staff that cow’s milk-based formula significantly increases NEC risk compared to human breast milk or donor breast milk fortifiers. Families whose premature infants were diagnosed with NEC after receiving these products in a NICU setting, whether the infant survived with injuries or died, may be eligible to file a claim. Cases are currently pending in both Illinois state courts and MDL 3026 in the Northern District of Illinois.
What did the April 9, 2026 Cook County verdict decide?
A Cook County jury awarded a combined $70 million to four families whose premature infants developed NEC after being fed Abbott’s Similac Special Care 24 in Chicago-area hospital NICUs. The award included $53 million in compensatory damages and $17 million in punitive damages. This was the first time multiple NEC cases were tried together in an Illinois state court. The punitive damages were allowed after the court found evidence suggesting Abbott may have concealed NEC risks associated with its product. All four infants survived but suffered severe complications, with three requiring surgery. Abbott has indicated it will appeal the verdict.
Why is the Inman v. Mead Johnson trial starting July 6, 2026 so important?
Inman v. Mead Johnson is the fourth federal bellwether trial in MDL 3026 and the first Enfamil case to survive summary judgment in the federal system. The prior three federal bellwethers — all involving Abbott’s Similac — were dismissed before trial after Judge Pallmeyer excluded plaintiffs’ causation experts under the Daubert standard. In Inman, Judge Pallmeyer denied Mead Johnson’s summary judgment motion and preserved the testimony of epidemiologist Dr. Logan Spector, making this the first federal NEC case where plaintiff experts will testify before a jury. A plaintiff verdict could trigger global settlement negotiations affecting all 798 active MDL cases; a defense verdict could substantially weaken federal plaintiffs’ leverage.
What is the current total of verdicts in the NEC baby formula lawsuit litigation, and what do they mean for settlement?
State courts have issued three significant plaintiff verdicts totaling more than $625 million: a $60 million Illinois Enfamil verdict in March 2024, a $495 million Missouri Similac verdict upheld on appeal, and the April 2026 $70 million Cook County verdict. The only defense verdict in the entire litigation was overturned after a Missouri judge found defense misconduct. Bloomberg Intelligence has estimated total combined NEC liability for Abbott and Mead Johnson at approximately $3 billion. These verdicts function as data points in mass tort settlement negotiations — the higher and more consistent the verdicts, the greater the pressure on defendants to resolve claims globally rather than continue litigating case by case.
How long do NEC baby formula lawsuits take, and is there a settlement yet?
As of June 2026, no global federal settlement has been announced for MDL 3026. Mass tort settlements in pharmaceutical and product liability litigation typically emerge after a series of bellwether trials establish plaintiff verdict potential and causation evidence survives appellate review — both conditions that are now being met in the NEC litigation. Individual state-court cases have resolved, but the 798 federal MDL cases remain unresolved. The timeline for a global settlement will depend heavily on the outcomes of the Inman v. Mead Johnson trial beginning July 6, 2026, and the Kelton v. Abbott trial beginning August 10, 2026. Families who have already filed claims should expect continued activity throughout the second half of 2026.
This content is provided for informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a licensed attorney in your jurisdiction.
Related reading: medical malpractice calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.